CHOP therapy for low and low-intermediate risk patients of advanced aggressive non-Hodgkin's lymphoma (JCOG9508, LSG17(CHOP))

CHOP therapy for low and low-intermediate risk patients of advanced aggressive non-Hodgkin's lymphoma (JCOG9508, LSG17(CHOP)) - CHOP therapy for low and low-intermediate risk patients of advanced aggressive non-Hodgkin's lymphoma (JCOG9508, LSG17(CHOP))

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000053

Enrollment

160

Registered

2005-08-09

Start date

1995-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

low and low-intermediate risk of aggressive non-Hodgkin's lymphoma

Interventions

Chemotherapy (8 courses of CHOP)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) histologically diagnosed non-Hodgkin's lymphoma with intermediate or high grade by Working Formulation, except for transformation from low grade lymphoma, ATL, T-lymphoblastic lymphoma, mycosis fungoideus, and Sezary syndrome. (2) Clinical stage of I-bulky, II, III, IV by Ann Arbor classification. (3) No previous chemotherapy or radiotherapy. (4) Age: between 15 and 69. (5) Performance Status: between 0 and 3. (6) Low or low-intermediate risk by International index (7) No organ dysfuction; neutrophil count>1200/ml, platelet count >75000/ml, ASTand ALT level <5 times the upper limit of the normal range, total bilirubin level < 2.0 mg/dl, serum creatinin level < 2.0mg/dl, no cardiac dysfunction. (8) Understanding and agreement of written informed consent.

Exclusion criteria

Exclusion criteria: 1) Complication; severe infection, heart failure, respiratory failure, hepatic failure, organic pulumonary disease, liver cirrhosis, acute or chronic hepatitis, renal failure. 2) Active or non-curable synchronous malignancy, except for cervical carcinoma in situ or basal carcinoma of the skin. 3) Psycological disorder like schizophrenia. 4) Heart disease which is deteriorated by anthracyclins, past history of myocardial infarction, or angina pectoris during 3 months before registration. 5) Pregnant or nursing . 6) Involvement of central nervous system 7) HIV infection

Design outcomes

Primary

Measure	Time frame
overall survival	—

Secondary

Measure	Time frame
Complete remission rate, Progression free survaval, adverse reaction/adverse effect	—

Countries

Japan

Contacts

Public ContactYoshitoyo Kagami, MD, PhD

JCOG9508 Coordinating Office Department of Hematology and Cell-therapy, Aichi Cancer Center Hospital

JCOG_sir@ml.jcog.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026